Showing 781-790 of 10904 results for "".
- Skin Tightening Induced by Fractional CO2 Laserhttps://practicaldermatology.com/news/20120918-skin_tightening_induced_by_fractional_co2_laser/2459735/Variations in mechanical properties of treated skin confirm skin tightening after CO2 fractional resurfacing laser treatment. (J Cosmet Dermatol; 11(3):201-6) Researchers measured dermal elasticity using suction applied with an in vivo skin elasticity meter (Cutometer). Significant improvement was s
- New School Initiative for Skin Cancer Preventionhttps://practicaldermatology.com/news/20120515-new_school_initiative_for_skin_cancer_prevention/2459798/La Roche-Posay recently collaborated with the Women's Dermatologic Society to launch “Time Out, Protect Your Skin” (TOPS) in schools to educate children and families about skin cancer prevention. New York City's Grace Church School was the first s
- Delicious Living magazine recognizes Wildly Natural Seaweed Body Creamhttps://practicaldermatology.com/news/20120229-delicious_living_magazine_recognizes_wildly_natural_seaweed_body_cream/2459862/The Delicious Living 2012 Beauty & Body Award for “Best New Product” went to The Seaweed Bath Co.'s Wildly Natural SeaweedTM Body Cream, the company announced. Delicious Living chose winners based on the products' efficacy without sacrificing purity, innovation and their dedication to raising standa
- Early Data Presented for Celotres™ for Keloid Scarshttps://practicaldermatology.com/news/20120224-early_data_presented_for_celotres_for_keloid_scars/2459866/Results from Halscion, Inc.'s KLEAR Study, which evaluated the initial safety and efficacy of Celotres™ in the treatment of keloid scars adjunctive to surgical excision, show a significant reduction (p=0.0110) in keloid recurrence, as compared to scientific literature, following a single treatment o
- FDA Advisory Arm Backs XELJANZ for PsAhttps://practicaldermatology.com/news/fda-advisory-arm-backs-xeljanz-for-psa/2458098/The United States Food and Drug Administration’s (FDA) Arthritis Advisory Committee recommends the approval of Pfizer's XELJANZ® (tofacitinib) for the treatment of adults with active psoriatic arthritis (PsA). The Arthritis Advisory Commit
- Do the FDA's Proposed Regulations on Tanning Bed Use Go Far Enough?https://practicaldermatology.com/news/do-the-fdas-proposed-regulations-on-tanning-bed-use-go-far-enough/2458646/As the comment period on the US Food and Drug Administration’s proposal to restrict tanning bed use winds down, researchers are weighing in on the proposal's merits and potential shortfalls. Investigators
- Ankit Agarwal Named New VP of Operations at Vialhttps://practicaldermatology.com/news/ankit-agarwal-named-new-vp-of-operations-at-vial/2461727/Ankit Agarwal is Vial’s new VP of Operatio
- Aditxt to Initiate First In-Human Clinical Trials with its Therapeutics Programs in Psoriasishttps://practicaldermatology.com/news/aditxt-to-initiate-first-in-human-clinical-trials-with-its-therapeutics-programs-in-psoriasis/2460724/Aditx Therapeutics, Inc.’s AditxtReprogramming Therapeutics Division is preparing its to begin first-in-human clinical
- AbbVie Presents Additional Phase 3 Data for Upadacitinibhttps://practicaldermatology.com/news/abbvie-presents-additional-phase-3-data-on-upadacitinib/2460591/Significantly more patients treated with AbbVie’s upadacitinib in both of the Measure Up 1 and 2 studies
- BTL HIFEM Devices Honored by Harper's Bazaar, NewBeautyhttps://practicaldermatology.com/news/btl-hifem-devices-honored-by-harpers-bazaar-newbeauty/2459976/BTL has received two new accolades from NewBeauty and Harper's Bazaar